The answer: Yes, but the relationship between schizophrenia and smoking is complex enough that cessation requires careful clinical management rather than standard cessation approaches applied without modification.

Why people with schizophrenia smoke at extremely high rates

Smoking rates in schizophrenia are among the highest of any population; estimates range from fifty to eighty percent, compared to roughly fifteen to twenty percent in the general population. This is not a coincidence or institutional culture alone. It reflects a specific neurobiological relationship.

Schizophrenia involves impaired nicotinic acetylcholine receptor function (specifically the alpha-7 subtype), producing deficits in sensory gating, attention, and cognitive processing that are core features of the illness. Nicotine temporarily normalizes alpha-7 receptor function, producing measurable improvements in sensory gating, working memory, and attention in people with schizophrenia.

This is pharmacologically real. The cognitive and perceptual improvement nicotine produces in schizophrenia is more pronounced than in the general population, thereby making smoking more powerfully reinforcing and more neurochemically relevant than standard addiction frameworks account for.

The antipsychotic medication complication

This is the most clinically important aspect of cessation in schizophrenia and the most commonly mismanaged.

Tobacco smoke, not nicotine itself, but the polycyclic aromatic hydrocarbons in smoke, induce liver enzymes that accelerate the metabolism of several antipsychotic medications, particularly clozapine and olanzapine. Smokers on these medications require significantly higher doses to achieve therapeutic blood levels than non-smokers.

When smoking stops, enzyme induction reduces within days. Drug metabolism slows. Blood levels of clozapine or olanzapine rise, sometimes to levels that produce toxicity, sedation, or adverse effects at doses that were previously therapeutic.

This is not a theoretical risk. It is a well-documented clinical phenomenon that has produced serious adverse events in people who quit smoking without adjusting their antipsychotic dose. Cessation in someone on clozapine or olanzapine requires proactive dose reduction coordinated with the prescribing psychiatrist before the quit date, not reactively after symptoms appear.

What cessation produces for schizophrenia

The short-term picture is complicated by the medication interaction and the temporary worsening of the cognitive deficits that nicotine was addressing.

The long-term picture is more positive than most clinicians and patients expect. Studies on long-term cessation in schizophrenia find (after the acute adjustment period) reduced cardiovascular risk, improved medication efficacy at lower doses, better metabolic outcomes, and for many people, stable or improved psychiatric symptoms compared to the smoking baseline.

The cardiovascular urgency is particularly relevant. People with schizophrenia have dramatically elevated cardiovascular mortality driven partly by antipsychotic metabolic effects, partly by lifestyle factors, and substantially by smoking. Cessation is the most impactful single cardiovascular intervention available in this population.

What works specifically

Psychiatrist involvement is mandatory, not optional. Cessation in schizophrenia is a clinical procedure, not a lifestyle change. The prescribing psychiatrist needs to be actively managing medication adjustment throughout the cessation process.

Varenicline is the most effective option for schizophrenia cessation; the EAGLES trial included people with schizophrenia and found no significant increase in psychiatric adverse events. It also partially addresses the alpha-7 receptor deficit that smoking was compensating for. Discuss explicitly with the psychiatrist.

Bupropion is an appropriate alternative; evidence supports its use in schizophrenia cessation with reasonable tolerability.

NRT reduces withdrawal intensity and is appropriate as a bridge, but does not address the alpha-7 receptor deficit that drove the smoking in the first place, making it less specifically targeted for this population than varenicline.

Cognitive support during cessation. The cognitive worsening of early cessation (impaired attention, working memory, processing speed) is more pronounced in schizophrenia than in the general population because the nicotinic receptor deficit is being unmasked. Structured daily routine, reduced cognitive demands during the acute withdrawal window, and explicit support from caregivers or case managers reduce the functional impact of this temporary worsening.

The one thing to hold onto

Smoking in schizophrenia was doing something real, addressing a receptor deficit that the illness itself produces.

Quitting removes that compensation temporarily, before the brain recalibrates. With proper medication management and clinical support, what follows is a body with significantly lower cardiovascular risk, a brain receiving properly dosed medication, and a nervous system no longer cycling through withdrawal dozens of times daily.

The path requires clinical management. The destination is better than the starting point. Both are true.